![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cue Biopharma Inc | NASDAQ:CUE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.7425 | 0.7265 | 1.18 | 0 | 09:05:21 |
Cue Biopharma will discuss current clinical and preclinical progress as well as strategy in the advancement of its oncology and autoimmune platforms and biologics.
Presentation DetailsJefferies Global Healthcare ConferenceDate and Time: Thursday, June 6 from 2:00 – 2:25 p.m. EDTWebcast Link: https://wsw.com/webcast/jeff302/cue/1681744 Presenter: Anish Suri, Ph.D., president and chief scientific officer, Cue Biopharma
Oppenheimer Novel Targets and Immunology SummitPanel Presentation Date and Time: Monday, June 24 from 11:00 – 11:40 a.m. EDTPanel: Repurposing Cancer Targets for ImmunologyPresenter: Anish Suri, Ph.D., president and chief scientific officer, Cue Biopharma
A live and archived webcast of the presentation for the Jefferies Global Healthcare Conference will be available on the Events page in the Investors and Media section of the Company’s website at www.cuebiopharma.com. The webcast will be archived for 30 days.
About Cue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.
Investor ContactMarie Campinell Senior Director, Corporate CommunicationsCue Biopharma, Inc.mcampinell@cuebio.com
Media ContactJonathan PappasLifeSci Communicationsjpappas@lifescicomms.com
1 Year Cue Biopharma Chart |
1 Month Cue Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions